

Brian Buebel

Principal, Deal Advisory & Strategy – Turnaround & Restructuring



KPMG LLP
1350 Avenue of the Americas
New York, NY 10019

Cell 917-612-3805
bbuebel@kpmg.com

Function and specialization

Brian is a member of the Deal Advisory and Strategy practice, specializing in Performance Transformation, guiding organizations through complex challenges and transitions.

Education, licenses and certifications

- MBA in Finance, Columbia University
- BS in Accounting, University of South Carolina
- Certified Public Accountant (Inactive)
- Certified Insolvency and Restructuring Advisor (Inactive)

Professional and industry experience

With nearly three decades of advisory and interim management experience in a range of industries, Brian boasts a diverse client portfolio with the last fifteen years focused on healthcare and life sciences organizations ranging from hospitals to pharmaceutical developers and device manufacturers. He has a proven track record of leading clients to successful outcomes, including refinancings and critical transactions. Brian's expertise spans strategic advisory, financial restructuring, transaction management, operational optimization, and regulatory compliance.

Having served in various interim leadership roles, including CEO, CRO, and Chief Transformation Officer, he brings valuable, hands-on experience in driving organizational change and achieving operational excellence.

Representative clients

- Leads work with stressed and distressed healthcare team, overseeing client project management, business development, and coaching of junior team members.
- Served as interim CEO & COO for a national DME provider, managing daily operations and leading sale and refinancing processes.
- Provided strategic and financial planning as Chief Restructuring Officer for a company specializing in oncology and neurodegenerative diseases.
- Led strategy development and performance improvement plans as interim President and Chief Restructuring Officer for Ameritox.
- Implemented turnaround plan and provided financial analysis as Chief Transformation Officer for a national toxicology lab.
- Advised pharmaceutical distributor on long-term business plan, executed performance improvement initiatives, and prepared for and executed Chapter 11 process.
- Provided strategic guidance and cash management expertise as Chief Restructuring Officer for a pharmaceutical development company, focusing on strategy development and creditor relations management.
- Facilitated significant refinancing efforts totaling \$630M for Nephron, a respiratory pharmaceutical company, as their financial advisor.
- Developed business plan and liquidity forecasting tools for a medical device company.
- Directed day-to-day operations and financial activities as deputy CRO for an institutional pharmacy, negotiating forbearance arrangements and overseeing due diligence processes, while also serving as a financial advisor for a publicly traded biopharmaceutical company and advising on operational restructuring and bankruptcy proceedings for Forum Health, a three-hospital system.
- Acted as part of the management team responsible for developing the 4-year business plan, achieving the goals set forth therein and managing relationships with companies in the Comdisco Ventures debt and equity portfolio.